Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission

The probability that adult patients with de novo acute myeloid leukemia (AML) receiving intensive chemotherapy in the absence of allogeneic hematopoietic stem cell transplantation (Allo-HCT) in first complete remission (CR1) will be disease-free at 10 years after diagnosis, a long-term surrogate of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood advances 2018-07, Vol.2 (13), p.1645-1650
Hauptverfasser:	Vasu, Sumithira, Kohlschmidt, Jessica, Mrózek, Krzysztof, Eisfeld, Ann-Kathrin, Nicolet, Deedra, Sterling, Lisa J., Becker, Heiko, Metzeler, Klaus H., Papaioannou, Dimitrios, Powell, Bayard L., Kolitz, Jonathan E., Moore, Joseph O., Baer, Maria R., Roboz, Gail J., Stone, Richard M., Byrd, John C., Carroll, Andrew J., Bloomfield, Clara D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Abnormal Karyotype Adolescent Adult Age Factors Allografts Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Disease-Free Survival Female Follow-Up Studies Hematopoietic Stem Cell Transplantation Humans Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - mortality Male Middle Aged Myeloid Neoplasia Retrospective Studies Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The probability that adult patients with de novo acute myeloid leukemia (AML) receiving intensive chemotherapy in the absence of allogeneic hematopoietic stem cell transplantation (Allo-HCT) in first complete remission (CR1) will be disease-free at 10 years after diagnosis, a long-term surrogate of cure, is unknown. To address this question, we examined 2551 AML patients (1607 aged
ISSN:	2473-9529 2473-9537
DOI:	10.1182/bloodadvances.2017015222